Page 1 | Search Results | Blood Neoplasia | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

Deferring treatment in hairy cell leukemia: is active surveillance safe?

Victoria M. Rogness, Xuefei Jia, Wei Wei, Brian T. Hill

Blood Neoplasia (2025) 2 (4): 100139.

https://doi.org/10.1016/j.bneo.2025.100139

Published: 2025

Journal Articles

Shelter in place: live CLL cells inside the bone marrow fibroblasts and its implication in residual disease persistence

Pin Lu, Carrie A Franzen, Aldana Vistarop, Andrey Efimov, SK Abrar Shahriyar, Shengchun Wang, Shilpa Rao, Marcus Messmer, Shazia Nakhoda, Edna Cukierman, Shuo Ma, Janusz Franco-Barraza, Juehua Gao, Y. Lynn Wang

Blood Neoplasia (2025) 2 (4): 100142.

https://doi.org/10.1016/j.bneo.2025.100142

Published: 2025

Includes: Multimedia, Supplemental data

Journal Articles

Neutrophil-mediated trogocytosis as a new mechanism of action of daratumumab

Mauro Lorenzo-Mohamed, Carla Vicario-Bueno, Andrea Díaz-Tejedor, Marta González-Rodríguez, Bárbara Castellanos, Janet Sotolongo-Ravelo, Laura San-Segundo, Lorena González-Méndez, Montserrat Martín-Sánchez, Mercedes Garayoa, Teresa Paíno

Blood Neoplasia (2025) 2 (4): 100151.

https://doi.org/10.1016/j.bneo.2025.100151

Published: 2025

Includes: Multimedia, Supplemental data

Journal Articles

Eμ-TCL1 mice with conditional human BCL2 knockin as novel B-cell lymphoma model for studying venetoclax effects in vivo

Ismini Halmer, Daniela Asslaber, Laura Beckmann, Gero Knittel, Hans Christian Reinhardt, Hamid Kashkar, Michael Hallek, Jens Löber, Björn Chapuy, Alexander Egle, Günter Krause, Alexandra da Palma Guerreiro, Lukas P. Frenzel

Blood Neoplasia (2025) 2 (4): 100143.

https://doi.org/10.1016/j.bneo.2025.100143

Published: 2025

Includes: Supplemental data

Journal Articles

Hypertension in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in ALPINE: a secondary analysis

June-Wha Rhee, Nicole Lamanna, Wassim Aldairy, Lipeng Chen, Jun Zhang, Dulce Ramirez, William B. White

Blood Neoplasia (2025) 2 (4): 100150.

https://doi.org/10.1016/j.bneo.2025.100150

Published: 2025

Includes: Supplemental data

Journal Articles

IgA or IgM MGUS less than 1.0 g/dL is at low risk of progression to neoplasm

Ashok P. Pai, Lue-Yen Tucker, David M. Baer

Blood Neoplasia (2025) 2 (4): 100140.

https://doi.org/10.1016/j.bneo.2025.100140

Published: 2025

Includes: Supplemental data

Journal Articles

Current landscape of frontline and relapsed follicular lymphoma trials

Lawrence Cheng Kiat Ng, Carla Casulo

Blood Neoplasia (2025) 2 (4): 100131.

https://doi.org/10.1016/j.bneo.2025.100131

Published: 2025

Journal Articles

A prospective study of prophylactic dexamethasone with glofitamab in relapsed/refractory large B-cell lymphoma

Blood Neoplasia (2025) 2 (4): 100147.

https://doi.org/10.1016/j.bneo.2025.100147

Published: 2025

Journal Articles

Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition

Ritul Sharma, Chunfen Zhang, Ravi Shah, Melanie M. Frigault, Amy J. Johnson, David Spencer Mangum, Luke D. Maese, Norman J. Lacayo, Aru Narendran

Blood Neoplasia (2025) 2 (4): 100148.

https://doi.org/10.1016/j.bneo.2025.100148

Published: 2025

Includes: Supplemental data

Journal Articles

Bendamustine switches TNF receptor superfamily signal from a survival to a death signal in B-cell lymphomas

Kensuke Nakao, Hiroshi Arima, Yui Arakawa, Tomoyasu Jo, Yujuan Guo, Iroha Morita, Tomohiro Taya, Toshio Kitawaki, Akifumi Takaori-Kondo, Momoko Nishikori

Blood Neoplasia (2025) 2 (4): 100157.

https://doi.org/10.1016/j.bneo.2025.100157

Published: 2025

Includes: Supplemental data

Journal Articles

Inferior survival in double refractory large B-cell lymphoma eligible for third-line CD19 CAR T-cell therapy

Chathuri Abeyakoon, Sita Bhella, Katrina Hueniken, Rachel Aitken, Carmel Waldron, Anca Prica, Vishal Kukreti, Robert Kridel, Abi Vijenthira, Christine Chen, Chloe Yang, Richard Tsang, David Hodgson, Danielle Rodin, Nauman Malik, Woodrow Wells, Michael Crump, John Kuruvilla

Blood Neoplasia (2025) 2 (4): 100164.

https://doi.org/10.1016/j.bneo.2025.100164

Published: 2025

Journal Articles

Orally available decitabine prodrug OR-2100 induces mitotic perturbation for the treatment of double-hit lymphoma

Keisuke Kidoguchi, Hiroshi Ureshino, Yuta Yamamoto, Ryo Yanagiya, Yuki Kurahashi, Yuki Fukuda-Kurahasi, Yumeka Mine, Shigehisa Aoki, Kazutaka Nakashima, Hiroaki Miyoshi, Koichi Ohshima, Atsushi Kawaguchi, Shinya Kimura

Blood Neoplasia (2025) 2 (4): 100155.

https://doi.org/10.1016/j.bneo.2025.100155

Published: 2025

Includes: Supplemental data

Journal Articles

Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia

Blood Neoplasia (2025) 2 (4): 100160.

https://doi.org/10.1016/j.bneo.2025.100160

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma

Yoshito Nishimura, Yiqun Han, Nadia Toumeh, Guneet Janda, Yu Fujiwara, Urshila Durani, Grzegorz S. Nowakowski, Jonas Paludo, Stephen M. Ansell, Jithma P. Abeykoon

Blood Neoplasia (2025) 2 (3): 100134.

https://doi.org/10.1016/j.bneo.2025.100134

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study

Trine Trab, Iman Chanchiri, Ahmed Ludvigsen Al-Mashhadi, Emma Berggren Dall, Stine Rasch, Mette Johansen, Simon Husby, Mikkel Runason Simonsen, Michael Roost Clausen, Thomas Stauffer Larsen, Jacob Haaber Christensen, Robert Schou Pedersen, Mikael Frederiksen, Mats Jerkeman, Christian Bjørn Poulsen, Laura Mors Haunstrup, Peter Brown, Tarec Christoffer El-Galaly, Kirsten Grønbæk

Blood Neoplasia (2025) 2 (3): 100128.

https://doi.org/10.1016/j.bneo.2025.100128

Published: 2025

Includes: Supplemental data

Journal Articles

Real-world performance of the CALGB 10403 regimen in young adults in the United States

Brandon DaSilva, Alicia Darwin, Amy Zhang, Rutu D. Vyas, Kathryn Russell, Jason S. Gilbert, Virginia Tan, Susan Feldt, Hannah Johnston, Emily C. Liang, Adam S. DuVall, Michaela Liedtke, Wendy Stock, Ryan D. Cassaday, Marc Schwartz, Jessica T. Leonard, Lori S. Muffly, Marlise R. Luskin

Blood Neoplasia (2025) 2 (3): 100111.

https://doi.org/10.1016/j.bneo.2025.100111

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysis

Inna Y. Gong, Michael Crump, Anca Prica, Andrew Calzavara, Ning Liu, Tiana Kordbacheh, Danielle Rodin, David Hodgson, Lee Mozessohn, Matthew C. Cheung, John Kuruvilla

Blood Neoplasia (2025) 2 (3): 100117.

https://doi.org/10.1016/j.bneo.2025.100117

Published: 2025

Includes: Supplemental data

Journal Articles

An antibody-drug conjugate targeting VpreB1 for the treatment of B-cell acute lymphoblastic leukemia

Peter M. Gordon, Robin L. Williams, Jason Ostergaard, Keegan C. Lee, Hannah N. Bui, Joseph M. Muretta, Bridget S. Wilson, Thomas Beder, Claudia D. Baldus, Luke Lambert, Benjamin E. Deonovic, Timothy Singleton, Sarah K. Tasian, Stuart S. Winter

Blood Neoplasia (2025) 2 (3): 100120.

https://doi.org/10.1016/j.bneo.2025.100120

Published: 2025

Includes: Supplemental data

Journal Articles

Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408

Frederique St-Pierre, Stephen M. Broski, Zequn Sun, Masha Kocherginsky, Betsy LaPlant, Matthew J. Maurer, Andrew Quon, Lucia Baratto, Hatice Savas, Lale Kostakoglu, Jane N. Winter, Thomas E. Witzig, Brad Kahl, Andrew M. Evens, Leo I. Gordon

Blood Neoplasia (2025) 2 (3): 100113.

https://doi.org/10.1016/j.bneo.2025.100113

Published: 2025

Includes: Supplemental data

Journal Articles

Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain

Elias Lagonik, Elyse C. Page, John B. Bruning, Laura N. Eadie, Susan L. Heatley, Matthew Greenwood, Chun Y. Fong, Andrew S. Moore, David T. Yeung, Timothy P. Hughes, Deborah L. White

Blood Neoplasia (2025) 2 (3): 100109.

https://doi.org/10.1016/j.bneo.2025.100109

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Deferring treatment in hairy cell leukemia: is active surveillance safe?

Shelter in place: live CLL cells inside the bone marrow fibroblasts and its implication in residual disease persistence

Neutrophil-mediated trogocytosis as a new mechanism of action of daratumumab

Eμ-TCL1 mice with conditional human BCL2 knockin as novel B-cell lymphoma model for studying venetoclax effects in vivo

Hypertension in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma in ALPINE: a secondary analysis

IgA or IgM MGUS less than 1.0 g/dL is at low risk of progression to neoplasm

Current landscape of frontline and relapsed follicular lymphoma trials

A prospective study of prophylactic dexamethasone with glofitamab in relapsed/refractory large B-cell lymphoma

Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition

Bendamustine switches TNF receptor superfamily signal from a survival to a death signal in B-cell lymphomas

Inferior survival in double refractory large B-cell lymphoma eligible for third-line CD19 CAR T-cell therapy

Orally available decitabine prodrug OR-2100 induces mitotic perturbation for the treatment of double-hit lymphoma

Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia

Outcomes of immune checkpoint inhibitor rechallenge in relapsed/refractory Hodgkin lymphoma

Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma: a Danish population-based study

Real-world performance of the CALGB 10403 regimen in young adults in the United States

Outcomes and factors influencing survival in patients with diffuse large B-cell lymphoma: a population-based analysis

An antibody-drug conjugate targeting VpreB1 for the treatment of B-cell acute lymphoblastic leukemia

Prognostic impact of extranodal disease on PET/CT in follicular lymphoma: results from a validation study with ECOG 2408

Activity of STAMP inhibitors in ABL2 rearranged acute lymphoblastic leukemia is dependent on the Abl2 SH3 domain

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only